CA
SYRS

CHI Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

CHI Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$5.12M Buy
1,299,359
+531,914
+69% +$1.99M 2.03% 13
2023
Q2 		$2.42M Hold
767,445
– – 0.73% 20
2023
Q1 		$2.05M Buy
+767,445
New +$2.98M 0.54% 21

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

CHI Advisors's SYRS Position: Q3 2023 in Review

CHI Advisors increased its Syros Pharmaceuticals, Inc. Common Stock (SYRS) stake by 69% in Q3 2023, buying an estimated $1.99M and bringing the position to 1,299,359 shares worth $5.12M. The position accounts for 2.03% of the portfolio, ranked #13.

CHI Advisors first reported a position in SYRS in Q1 2023 and has held it in 3 quarters since. 48 funds tracked by Wall St. Rank hold SYRS as of Q3 2023.

  • CHI Advisors held 1,299,359 shares of Syros Pharmaceuticals, Inc. Common Stock worth $5.12M as of Q3 2023.
  • CHI Advisors bought 531,914 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $1.99M.
  • Syros Pharmaceuticals, Inc. Common Stock made up 2.03% of CHI Advisors's portfolio in Q3 2023, its #13 holding.
  • CHI Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2023 and has held it in 3 quarters since.
  • 48 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.